NBC Securities
PTGX icon

NBC Securities’s Protagonist Therapeutics PTGX Stock Holding History

NBC Securities’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$223K Sell
1,586
-959
-38% -$137K 0.02% 828
2026
Q2 		$312K Sell
2,545
-2
-0.1% -$209 0.02% 694
2026
Q1 		$268K Sell
2,547
-430
-14% -$38.1K 0.02% 741
2025
Q4 		$260K Buy
2,977
+19
+0.6% +$1.56K 0.02% 744
2025
Q3 		$196K Buy
2,958
+393
+15% +$22.3K 0.02% 848
2025
Q2 		$141K Buy
+2,565
New +$123K 0.01% 944

Other funds holding PTGX

UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 20.64% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return

NBC Securities's PTGX Position: Q3 2026 in Review

NBC Securities reduced its Protagonist Therapeutics (PTGX) stake by 38% in Q3 2026, selling an estimated $137K and leaving 1,586 shares worth $223K. The position accounts for 0.02% of the portfolio, ranked #828.

NBC Securities first reported a position in PTGX in Q2 2025 and has held it in 6 quarters since. The position peaked at $312K in Q2 2026. 237 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • NBC Securities held 1,586 shares of Protagonist Therapeutics worth $223K as of Q3 2026.
  • NBC Securities sold 959 Protagonist Therapeutics shares in Q3 2026, an estimated $137K.
  • Protagonist Therapeutics made up 0.02% of NBC Securities's portfolio in Q3 2026, its #828 holding.
  • NBC Securities first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • NBC Securities's Protagonist Therapeutics position peaked at $312K in Q2 2026.
  • 237 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on NBC Securities's 13F filing for Q3 2026, filed 26 Oct 2026.